Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?

Anti-CTLA-4 and anti-PD-1/PD-L1 immune checkpoint inhibitors are therapeutic monoclonal antibodies that do not target cancer cells but are designed to reactivate or promote antitumor immunity. Dosing and scheduling of these biologics were established according to conventional drug development models...

Descripción completa

Detalles Bibliográficos
Autores principales: Maritaz, Christophe, Broutin, Sophie, Chaput, Nathalie, Marabelle, Aurélien, Paci, Angelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760805/
https://www.ncbi.nlm.nih.gov/pubmed/35033167
http://dx.doi.org/10.1186/s13045-021-01182-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760805/
https://www.ncbi.nlm.nih.gov/pubmed/35033167
http://dx.doi.org/10.1186/s13045-021-01182-3

Ejemplares similares